Dr. Tomas Reinert presents a poster at San Antonio Breast Cancer Symposium 2019

Dr. Tomas Reinert presents a poster at San Antonio Breast Cancer Symposium 2019, US, showing that ESR1 mutations are not a mechanism of primary resistance to aromatase inhibitors in ER-positive breast cancer treated with neoadjuvant endocrine therapy. The study was part of his Ph.D. thesis at the Universidade Federal do Rio Grande do Sul in collaboration with several other institutions including LACOG.